Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of a Single Dose of Pembrolizumab in HIV-Infected Patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 08 Jun 2022 Planned End Date changed from 20 Nov 2022 to 20 Nov 2024.
- 08 Jun 2022 Planned primary completion date changed from 30 May 2022 to 30 May 2024.
- 18 Mar 2020 Planned End Date changed from 30 Nov 2022 to 20 Nov 2022.